Default company panoramic image

Pop Test Cortisol LLC

Pop Test Cortisol acquires chemotherapy sensitizer Org34517 from Merck & Co. Breast Cancer growth slowed and reversed

  • Stage Product In Development
  • Industry Biotechnology
  • Location Cliffside Park, NJ, USA
  • Currency USD
  • Founded August 2010
  • Employees 10
  • Website

Company Summary

Pop Test Cortisol LLC is a research and development company focusing on the development of a drug called ORG34517 that was acquired from Merck in 2010. It is the company’s intent to provide clinical proof of concept in key oncology indications and possibly selected CNS indications and then to sell the company to a 3rd party for further development and commercialization.
Org34517 is one of a new class of therapeutic agents designe


  • Default avatar
    Randice Lisa Altschul

    Inventor/Entrepreneur. The WORLD INTELLECTUAL PROPERTY ORGANIZATION has named Randi Altschul, one of the WORLD’S NOTABLE INVENTORS.

  • Default avatar
    Dr. Neil Theise
    Chief Medical Director

    Neil Theise, MD is a diagnostic liver pathologist and adult stem cell researcher in New York City, where he is Professor of Pathology and of Medicine. His research revised understandings of human liver microanatomy which, in turn, led directly to identification of possible liver stem cell niches and the marrow-to-liver regeneration pathway. He is considered a pioneer of multi-organ adult stem cell plasticity and has published on that topic in Sci

  • Default avatar
    John Gregg
    Drug Development Director

    John Gregg is a veteran of the pharmaceutical industry with more than 25 years experience. His experience and expertise range from Director of the Product Evaluation Group for Global Analytics at Pfizer Global Pharmaceuticals, to the Specialty Market Research at Novartis, the Marketing services of Johnson & Johnson and Bristol- Myers Squibb. John’s ability in targeting unique and novel products and the commercialization of same brings a wealth of

  • Default avatar
    Pharm Olam International

    Pharm-Olam International is a multi-national contract research organization offering a wide range of comprehensive, clinical research services to the pharmaceutical, biotechnology and medical device industries. From Phase I to Phase IV, POI focuses on delivering the highest quality data, achieving targeted enrollment and meeting projected timelines.

  • Default avatar
    Dr. Hirohisa Yano
    Pre-Clinical Study Director

    Chairman of Pathology of Kurume University School of Medicine, Kurume, Japan


  • Default avatar
    Caesar, Revise, Bernstein, Cohen & Pokotilow